Collaboration will leverage Belharra’s proprietary, non-covalent chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targets Sanofi to lead further preclinical, clinical and …
Need help?
Contact usCollaboration will leverage Belharra’s proprietary, non-covalent chemoproteomics platform to identify and advance small molecules against Sanofi-designated immunology targets Sanofi to lead further preclinical, clinical and …